Clinical Trials
8 trialsNCT06413680 2026-04-28
BrILliance
Regeneron Pharmaceuticals
Phase 1/2 Recruiting
NCT04913220 2026-02-04
A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers (Pegathor Skin 201)
Sanofi
Phase 1/2 Terminated
NCT05259696 2025-08-20
GLIMMER-01
Palleon Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT05864144 2025-08-15
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Sensei Biotherapeutics, Inc.
Phase 1/2 Active not recruiting
NCT04339062 2025-04-23
CONTRAC
Dana-Farber Cancer Institute
Phase 1/2 Completed
NCT06090266 2025-01-07
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
OncoResponse, Inc.
Phase 1/2 Recruiting
NCT05094804 2023-11-02
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
OncoResponse, Inc.
Phase 1/2 Unknown
NCT03684785 2022-04-07
Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors
Exicure, Inc.
Phase 1/2 Terminated